I-Corps: Preventing Rolling Veins During IV Insertion

I-Corps：在静脉注射期间防止静脉滚动

• 批准号: 2053194
• 负责人: Guy German
• 金额: $ 5万
• 依托单位: SUNY at Binghamton
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-02-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2053194&HistoricalAwards=false
• 关键词: Corps; Preventing; Rolling; Veins; During

The broader impact/commercial potential of this I-Corp project will result in the ability to decrease vein movement during venipuncture. In situations in which a patient requires intravenous (IV) fluids, this device could reduce the time it takes to successfully insert a needle by stabilizing the vein for a faster insertion time. This device has a reduced cost in comparison to vein tracking systems which could save hospitals money. This technology also has the potential to reduce the number of specialty staff needed for needle insertion and may reduce the human and financial burdens associated with venipuncture complications, including hematomas, injury, wounds, anxiety, hypertension, and infections, especially for at-risk patients, such as those who are elderly, diabetic, or immunocompromised. There are currently over 6,000 hospitals in the US alone. All hospitals perform venipuncture through intravenous therapy insertions or taking blood samples, with over 230 million IVs placed every year. This I-Corps project focuses on constructing a method for stabilizing veins during the venipuncture procedure. The technology is a single-use plastic device that is placed on the forearm of a patient by a medical professional. A slight pressure is applied on the device into and up the arm in order to isolate and elevate the vein in preparation for needle insertion. The device aims to immobilize the vein to reduce the complications associated with the phenomena known as "rolling veins" in which the vein moves and can result in an unsuccessful needle insertion. A model vein was created in order to test the movement of the vein both with and without the device. The testing showed that the device decreased the maximum displacement of the vein by 84% in comparison to tested vein displacement without the device. The maximum displacement of the vein with the device was calculated to be 0.20 mm while the maximum displacement of the vein without the device was calculated to be 1.26 mm.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

该I-Corp项目的更广泛影响/商业潜力将导致能够减少静脉穿刺期间的静脉运动。在患者需要静脉注射（IV）液体的情况下，该设备可以通过稳定静脉缩短插入时间来减少成功插入针头所需的时间。与静脉跟踪系统相比，该设备的成本更低，可以为医院节省资金。该技术还具有减少针插入所需的专业人员数量的潜力，并且可以减少与静脉穿刺并发症相关的人力和经济负担，包括血肿、损伤、伤口、焦虑、高血压和感染，特别是对于高危患者，例如老年人、糖尿病患者或免疫功能低下的患者。目前，仅在美国就有6,000多家医院。所有医院都通过静脉治疗插入或采集血液样本进行静脉穿刺，每年有超过2.3亿次静脉注射。这个I-Corps项目的重点是构建一种在静脉穿刺过程中稳定静脉的方法。该技术是一种一次性塑料器械，由医疗专业人员放置在患者前臂上。在器械上施加轻微压力，进入手臂并向上，以隔离和抬高静脉，为针头插入做准备。该装置旨在使静脉平滑，以减少与被称为“滚动静脉”的现象相关的并发症，在该现象中，静脉移动并且可能导致不成功的针插入。创建了一个模型静脉，以测试使用和不使用器械时静脉的运动。测试表明，与不使用该器械的测试静脉位移相比，该器械使静脉的最大位移减少了84%。使用该器械时静脉的最大位移计算为0.20 mm，而不使用该器械时静脉的最大位移计算为1.26 mm。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。